Prostate cancer is the most common cancer in men. Surgery and radiotherapy offer high-cure rates in cases confined to the prostate gland, with 5-year control rates exceeding 70% ([@bib17]). Extracapsular extension or seminal vesicle involvement, as well as high Gleason score and PSA levels, is, however, linked to high postoperative and post-radiotherapy relapse rates, with long-term control rates falling below 50% ([@bib7]; [@bib2]; [@bib26]).

To improve radiotherapy results, investigation has to consider three main directions. First, normal tissue tolerance has to increase either through technological innovations improving the accuracy of dose distribution or through selective normal tissue cytoprotective agent delivery. Second, the intrinsic radiosensitivity of tumours must be enhanced either by tumour-targeting agents or by radiotherapy quality adjustments, including altered fractionation, particle radiation or hyperthermia. Finally, tumours able to exhibit the accelerated repopulation phenomenon, a complex tumour reaction to radiation damage, should be targeted either with accelerated radiotherapy schemes or with agents, unknown as yet, preventing this very phenomenon.

Recent clinical radiobiological data have revealed important aspects on the sensitivity of prostate cancer cells, implying low *α/β*-ratios (1--2 Gy, ([@bib31]; [@bib6])), and overall better responsiveness to large radiotherapy fractions. Therefore, hypofractionation is a reasonable approach, as indeed randomised trials have shown good local control without increase of toxicities ([@bib32]; [@bib4]). Although prostate cancer is generally considered to have low proliferation ability, previous studies have shown increased proliferation rates in a subset of tumours, which indicated failure of conventionally fractionated radiotherapy regimens ([@bib3]; [@bib19]). Hypofractionated and accelerated radiotherapy (HypoARC) may, therefore, be a better therapy option for such subgroups of patients. Clinical trials from our group confirmed the good tolerance and high activity of such regimens ([@bib12], [@bib13]).

In the current study, we examine whether prostate tumours with high cancer cell MIB1 proliferation index or hypoxic tumours with high glycolytic rates as assessed by the overexpression of the lactate dehydrogenase LDH5 isoenzyme ([@bib14]) affect the outcome of prostate cancer patients treated with HypoARC. *In vitro* experiments with the PC3 and DU145 prostate cancer cell lines were also performed to further investigate the role of LDHA gene in prostate cancer radioresistance.

Materials and methods
=====================

Archived formalin-fixed paraffin-embedded tissues from 83 biopsy specimens from prostate cancer patients treated with radical radiotherapy (with or without androgen deprivation) were retrieved from our pathology department. An additional 95 surgical specimens from prostate cancer patients treated with radical prostatectomy were retrieved to form a control base with surgical (larger) tissue samples to validate the reliability of immunohistochemical marker assessment in bioptic material and their correlation with histopathological variables. The study has been approved by the Democritus University of Thrace Research and Ethics Committee. Details on the technique and results of hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC) have been previously reported ([@bib15], [@bib13]). Briefly, a total of 15 fractions or 3.5 Gy per fraction is delivered within 19 days to the prostate and seminal vesicles. Patients with PSA \>10 ng ml^−1^ or Gleason score ⩾7 also receive pelvic irradiation (concomitant boost technique: 2.7 Gy × 14 fractions to the pelvis and 0.8 Gy to the prostate and seminal vesicles followed by a 15th fraction of 3.5 Gy confined to the prostate area).

Out of 178 cases, 152 (85.4%) had disease confined to the prostate gland (T1,2-stage) and 26/178 (14.6%) had extracapsular or seminal vesicle extension (T3-stage). The above staging was pathological for patients treated with surgery, and was based on biopsy, CT and MRI pelvic and prostate imaging for patients treated with radical radiotherapy. The presence of distant metastasis was assessed with CT scan of the chest and abdomen and with bone scintigraphy. Patients with histologically confirmed node involvement or radiological evidence of node or distant metastasis were excluded from the study. None of the patients undergoing radiotherapy had radiologically confirmed enlarged nodes; the presence of extraprostatic involvement was assessed with CT and MRI imaging. The Gleason score ranged from 4 to 10 (median 5). A low Gleason score of 4--5 characterised 96/178 (53.9%) cases, a medium of 6--7 characterised 51/178 (28.7%) and a high score of 8--10 characterised 31/178 cases (17.4%). Pre-radiotherapy maximum PSA levels were also available, ranging from 3.3 to 52 (median 10). ROC analysis of PSA levels against biochemical relapse following radiotherapy showed a specificity value \>70% for PSA levels \>15 mg ml^−1^ and this was used as a cutoff point (low *vs* high). Pre-operative PSA levels ranged from 2.1 to 22 (median 9.1). A detailed report o f patient and histopathological characteristics of tumours in the radiotherapy and surgery groups is shown in [Table 1](#tbl1){ref-type="table"}.

The median follow-up of patients treated with radiotherapy was 36 months (range 6--75). The minimum follow-up for patients alive was 24 months. PSA levels were assessed every 6 months. Within the available follow-up time interval, biochemical failure was recorded in 12/83 patients (14.4%). In these patients, CT scans of the chest, abdomen and pelvis, a bone scintigraphy, transrectal colour Doppler ultrasonography and prostate MRI were performed in an attempt to identify local or distant relapse. Out of 83 patients, local recurrence could be confirmed in 6 (7.2%) patients (3 of them with concurrent confirmation of distant metastasis).

Immunohistochemistry
--------------------

The prostate carcinomas were stained immunohistochemically for the MIB1 protein using the automated Bond-max system (Leica Microsystems, San Diego, CA, USA). Sections of size 3 *μ*m were cut from formalin-fixed paraffin-embedded tissues and dried for 30 min at 80 °C. The slides were then covered by Bond Universal Covertiles (Leica Microsystems) and placed into the Bond-max instrument. This was followed by deparaffinisation of tissue on the slides with Bond Dewax Solution (Leica Microsystems) at 72 °C for 15 min; heat-induced antigen retrieval with Bond Epitope Retrieval Solution 2 (Leica Microsystems) for 30 min at 100 °C; peroxide block placement on the slides for 5 min at room temperature; and incubation with the MIB1 primary antibody (DAKO, Glostrup, Denmark) at a dilution of 1 : 75 for 20 min. The subsequent steps of the procedure were performed at room temperature and included: incubation with Post Primary reagent (Leica Microsystems) for 10 min. Colour was developed using 3,3′-diaminobenzidine tetrahydrochloride (DAB). The sections were then counterstained with hematoxylin for 5 min, dehydrated and mounted. Normal immunoglobulin-G was substituted for the primary antibody as negative control.

For LDH5 immunohistochemistry, sections of 3 *μ*m thickness were deparaffinised and placed in antigen retrieval target solution of pH 9.0 (DAKO), followed by microwaving (3 × 5 min). Non-specific binding was blocked in normal rabbit serum at a dilution 1 : 20 for 30 min (DAKO, X0902). No rinsing was performed. The primary sheep polyclonal antibody to LDH5 isoenzyme (ab9002, Abcam, Cambridge, UK) was applied at a dilution 1 : 200 overnight at 4 °C. Following washing with PBS, endogenous peroxidase was quenched with Peroxidase Block (code: K0679, DAKO) for 10 min. It was followed by washing with PBS. Sections were then incubated with a secondary antibody (Biotinylated Secondary rabbit-antisheep; DAKO, P0163) at 1 : 100 for 30 min, and washed in PBS. Streptavidin-HRP (K0679, Dako) was applied for 30 min, and sections were again washed in PBS. The colour was developed by 15 min incubation with DAB solution, and sections were counterstained weakly with haematoxylin. Normal immunoglobulin-G was substituted for the primary antibody as negative control.

The percentage of cells with nuclear MIB1 expression was assessed in all available fields ( × 200 magnification) and the mean value was used to score each case. The pattern of LDH5 expression in prostatic cancer cells is mixed nuclear and cytoplasmic. The proportion of tumour cells expressing cytoplasmic or nuclear reactivity to LDH5 was separately recorded after examining the entire tumour area at × 200 magnification. A previously reported grading system, combining both nuclear and cytoplasmic expression, was used to score cases as negative, bearing low or high LDH5 reactivity ([@bib16], [@bib15]). Briefly, tumours with strong cytoplasmic expression in \>50% of cancer cells and/or tumours with nuclear expression in \>10% of cancer cells were considered to have high LDH5 reactivity. For MIB1 index, the 5% value (median value in the radiotherapy biopsy samples) was used to group cases as of high or low proliferation index.

*In vitro* experiments
----------------------

Human prostate cancer cell lines PC3 and DU145 (CLS Cell Lines Service, GmbH, Eppelheim, Germany) were cultured and maintained using standard procedures. Four LDHA siRNAs were custom synthesised (GenePharma Co, Shanghai, China), pooled and used at 50 n[M]{.smallcaps} to transfect cancer cells using HiPerfect (QIAGEN, Gaithersburg, MD, USA) for 24 h; the silencing efficiency of siRNAs was confirmed both by western blot after 48 h in total.

For immunoblotting, whole-cell lysates from both cell lines were prepared in RIPA buffer (Sigma-Aldrich Chemie Gmbh, Munich, Germany; cat. no. R0278) with the complete mini protease inhibitor cocktail (Roche Diagnostics, GmbH) and phosphatase inhibitor cocktail (Cell Signaling Technology Inc.). Proteins of each lysate (20 *μ*g) were resolved by discontinuous SDS gels using 10% separating and 5% staking gels and transferred to a PVDF membrane (pore size: 0.45 *μ*m, Millipore Corp., cat. no. IPVH00010). All different experimental condition lysates were loaded on the same gel and transferred on the same membrane. Following blocking with TBS (pH 7.5) containing 0.1% (v/v) Tween 20 and 5% (w/v) non-fat dried milk for 2 h at room temperature, membranes were hybridised at 4 °C overnight with the primary sheep polyclonal anti-LDH5 antibody (1 : 5000, Abcam; cat. no. ab9002). The membranes were then hybridised for 2 h at room temperature with the secondary antibody, rabbit polyclonal to sheep IgG (H+L)-HRP conjugate (1 : 10 000; DAKO, Denmark; PO163). Each of these blots was then stripped (1.5% w/v glycine, 0.1% w/v SDS, 1% v/v Tween 20, pH 2.2) twice for 10 min, washed twice with PBS for 10 min each and washed twice with TBS-T for 5 min, at room temperature. Then the blocking stage took place, as described previously, followed by reprobing of the membranes with a rabbit primary anti-beta actin antibody (1 : 5000, Abcam; cat. no. ab75186) to confirm equal loading of the gels. The secondary antibody used was the goat polyclonal to rabbit IgG (H+L)-HRP conjugate at a dilution of 1 : 15 000 (Biorad, Hercules, CA, USA; cat. no.170-6515). The images of the blots were captured utilising Chemidoc MP imaging system (Biorad), and they were analysed by the accompanied Image Lab software.

For cell survival experiments, cells were placed in 96-well plates at a concentration of 250 cells per well for DU145 and 500 cells per well for PC3 (lower proliferation rates). Irradiation of plates was performed using a 6-MV beam of a Linear Accelerator (PRECISE; ELEKTA) endowed with MultiLeaf Collimator. For multidose irradiation of columns of wells within the same 96-well plate, a previously validated and reported technique was used ([@bib1]). Cell proliferation and survival experiments were performed using the AlamarBlue assay (Serotec; cat. no. BUF012B), as previously validated by our group ([@bib33]). A microplate reader (FLUOstar Omega; BMG LABTECH GmbH, Ortenberg, Germany) was used to assess fluorescence. At measurement, gain adjustment is performed against the well of the maximum fluorescence (wells with alamarblue and vitamin C). The relative fluorescence units (RFU) are recorded for each well at a chosen time point. For every irradiated well the RFU ratio is calculated as follows:

The mean RFU-ratio value is calculated for all wells receiving the same radiation dose. Survival curves are produced plotting radiation dose (Gy) against mean RFU ratio (corresponding to the % of cell survival).

Statistical analysis
--------------------

Statistical analysis was performed using the GraphPad Prism 5.0 and the SPSS 15.0 (SPSS Inc., Chicago, IL, USA) packages. All data were considered either as categorical or as continuous variables. ROC analysis was used to define the specificity cutoff value for PSA regarding biochemical relapse. The Fisher\'s exact *t*-test, chi-square or unpaired two-tailed *t*-test was used to compare categorical variables as appropriate. Linear regression analysis was employed to assess correlations between continuous variables. Biochemical relapse-free (BRFS) and local relapse-free (LRFS) survival was estimated using Kaplan--Meier curves. Curves were compared using the log-rank test (Mantel--Haenszel). A Cox proportional hazard model including all pre-outcome variables was used to further test the independent significance of variables that proved to be of significance in univariate analysis. A two-tailed *P*-value of \<0.05 was considered to be significant.

Results
=======

Expression patterns
-------------------

LDH5 was expressed in the cytoplasm and the nuclei of cancer cells ([Figure 1](#fig1){ref-type="fig"}). Overall, the percentage of cells with strong cytoplasmic reactivity ranged from 0 to 100% (median 60%) among cases. The percentage of cancer cells with nuclear expression ranged from 0 to 100% (median 10%). [Table 2](#tbl2){ref-type="table"} shows the detailed analysis in biopsy and surgical specimens. The % of cells with nuclear MIB1 expression ([Figure 1](#fig1){ref-type="fig"}) ranged from 0 to 30 (median 3). Cases are grouped according to the LDH5 and MIB1grading system reported in the methods. There was no statistical difference between radiotherapy (biopsy) and surgery (surgical specimen) groups.

Association among variables
---------------------------

[Table 3](#tbl3){ref-type="table"} reports the association among LDH5, MIB1, T-stage, Gleason score and PSA levels. Overall, high LDH5 was directly related to high MIB1 index (*P*\<0.0001), high Gleason score (*P*=0.02), T3-stage (*P*=0.001) and high PSA levels (*P*=0.02). Similar associations were obtained in the biopsy and surgical specimens separately. MIB1 proliferation index was also directly related to high Gleason score (*P*\<0.0001), T3-stage (*P*=0.0008) and high PSA levels (*P*=0.0002).

Linear regression analysis of continuous variables also confirmed a direct association of cytoplasmic LDH5 expression with MIB1 (*P*=0.001, *r*=0.23) and with Gleason score (*P*=0.001, *r*=0.26). A significant association of MIB1 with Gleason score was also noted (*P*\<0.0001, *r*=0.43).

Biochemical failure and local relapse
-------------------------------------

[Table 4](#tbl4){ref-type="table"} reports the univariate and multivariate analysis of BRFS (Kaplan--Meier analysis) and of local relapse of patients treated with radiotherapy. High Gleason score, high MIB1, PSA levels and LDH5 were significantly related to poor BRFS (*P*=0.007, 0.01, 0.01 and 0.01, respectively). LDH5, together with the PSA levels, was independently related to biochemical failure (*P*=0.05 and 0.03, respectively). [Figure 2](#fig2){ref-type="fig"} shows the Kaplan--Meier BRFS curves for MIB1 and LDH5.

Regarding local relapse, Gleason score (*P*=0.04) and, more strongly, high PSA levels (*P*=0.003) were significantly related to poor local control. LDH5 was also significantly associated (*P*=0.03). None of the examined variables was an independent predictor in multivariate analysis.

Prostate cancer cell line radiosensitivity
------------------------------------------

Western blot analysis showed intense expression of LDH5 by both cell lines and effective silencing of the LDHA gene using LDHA siRNAs ([Figure 3A](#fig3){ref-type="fig"}). The PC3 cell line was far more resistant to radiation compared with the DU145 one; the 50% dose response (DR50) met at 11.7 and 4.3 Gy, respectively ([Figures 2B and C](#fig2){ref-type="fig"}). Silencing of LDHA displaced the survival curves to the left in both cell lines, showing an important radiosensitisation. The DR50 was reduced to 8.15 Gy and to 2 Gy for the PC3 and DU45 cell lines, respectively ([Figure 2B and C](#fig2){ref-type="fig"}).

Discussion
==========

Although prostate cancer is considered a slowly growing tumour, this certainly does not apply to all cases. High Gleason score, and also advanced local stage, have been associated with high cancer cell proliferation index in several published studies ([@bib29]; [@bib22]; [@bib5]; [@bib20]). This has been also confirmed in the current study, where a fraction of about 25% of tumours treated either with radiotherapy or with surgery showed 10--20% of cancer cells undergoing active cell cycle and, indeed, such tumours were frequently of high Gleason score and expressed extraprostatic involvement.

High proliferation index has also been correlated with increased biochemical failure following prostatectomy ([@bib9]; [@bib30]; [@bib24]). In a study by [@bib19], on 108 patients who underwent conventional radiotherapy in the context of the RTOG 86-10 protocol, a ki67 proliferation index \>3.5% was associated with distant metastasis. Several studies also showed that recurrent tumours following radiotherapy bear a higher-than-initial proliferation rate ([@bib8]; [@bib27]). In our study, high MIB1 index was, indeed, related to high rates of biochemical failure. Local control, however, seemed not to be affected by MIB1, which may show that acceleration of radiotherapy may be an important factor of efficacy in such tumours. Gleason score and high PSA (\>15 ng ml^−1^) levels were the most important factors defining local relapse, implying that such features go along with biological pathways related to intrinsic radioresistance, even to large radiotherapy fractions.

Intratumoral hypoxia may be a component of this resistant tumour biology. In a recent study, direct oxygen measurements of prostate cancer showed that hypoxia was the only factor predictive of local recurrence following radiotherapy ([@bib23]). Hypoxia inducible factor 1 is overexpressed in prostate carcinomas ([@bib18]) and confers radioresistance to prostate cancer cells ([@bib11]; [@bib10]). HIF transcriptionally regulates the expression of LDHA gene ([@bib28]. LDH5 is the isoenzyme composed by 4 LDHA subunits, and has the most potent activity in driving anaerobic cell metabolism to obtain ATP from pyruvate transformation to lactate, in cases where the aerobic pathway is suppressed or impossible to function under the lack of oxygen ([@bib21]). LDH5 is, therefore, an important marker of intrinsic hypoxia and glycolytic metabolism linked to radioresistance and chemoresistance ([@bib14], [@bib16]). In the current study, we found that LDH5 is overexpressed in ∼65% of prostate carcinomas and this was directly linked to high Gleason score, proliferation index and extracapsular invasion. A significant association with biochemical relapse and also with local relapse was observed, which supports the idea that hypoxia and metabolism pathways may underlie the radioresistance of some prostate tumours to radiotherapy, regardless of the fraction size and the overall treatment time. The experimental evidence that HIF inhibitors, such as PX-478, overcome hypoxia-related radioresistance ([@bib25]) encourages the combination of such agents with HypoARC. In the current study, silencing of the LDHA gene resulted in important radiosensitisation in two widely used prostate cancer cell lines, namely the PC3 and the DU145.

It is concluded that a high proliferation index, as noted in one-fourth of prostate carcinomas, is linked to biochemical failure following radiotherapy. The current study, however, provides evidence that acceleration of radiotherapy may help overcome the ominous effect of both proliferation rate and extracapsular extension on the local tumour control. Hypoxia and anaerobic metabolism may be an important component of prostate cancer radioresistance that counteracts the efficacy of radiotherapy, including hypofractionation. Whether LDHA or hypoxia targeting agents in combination with HypoARC may further improve the efficacy of hypofractionation and of acceleration of radiotherapy is a hypothesis to test in clinical trials.

The study has been financially supported by the Tumour and Angiogenesis Research Group.
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![**Immunohistochemical expression of MIB1 in the nuclei (**A**) and of LDH5 in the cytoplasm and nuclei (**B**) of prostate cancer cells (magnification × 200).**](bjc2014158f1){#fig1}

![**Kaplan--Meier biochemical relapse (a--e) and local relapse-free survival (f) of patients treated with hypofractionated and accelerated radiotherapy stratified for T-stage (A), Gleason score (B), PSA levels (C), MIB1 index (D) and LDH5 expression (E and F).**](bjc2014158f2){#fig2}

![**Western blot analysis of LDHA protein expression confirms suppression of LDHA gene using specific siRNAs (A).** Such a silencing resulted in important radiosensitisation of PC3 radioresistant (**B**) and DU145 radiosensitive cell lines (**C**).](bjc2014158f3){#fig3}

###### Patient and disease characteristics

  **Parameter**                            **All cases (178 pts)**   **Radiotherapy (83 pts)**   **Surgery (95 pts)**
  ---------------------------------------- ------------------------- --------------------------- ----------------------
  Age (median, range)                      68 (44--88)               69 (52--79)                 63 (44--75)
  **T-stage[a](#t1-fn2){ref-type="fn"}**                                                         
  T1, 2                                    152 (85.4)                75 (90.3)                   77 (81.0)
  T3                                       26 (14.6)                 8 (9.7)                     18 (19.0)
  **N-stage**[a](#t1-fn2){ref-type="fn"}                                                         
  N0                                       178 (100)                 83 (100)                    95 (100)
  N+                                       0 (0)                     0 (0)                       0 (0)
  **Gleason score**                                                                              
  4--5                                     96 (53.9)                 42 (50.6)                   54 (56.8)
  6--7                                     51 (28.7)                 26 (31.3)                   25 (26.3)
  8--10                                    31 (17.4)                 15 (18.1)                   16 (16.9)
  **PSA levels (mg ml**^**−1**^)                                                                 
  \<10                                     94 (52.8)                 43 (51.8)                   51 (53.7)
  10--15                                   32 (18.0)                 12 (14.5)                   20 (21.1)
  \>15                                     52 (29.2)                 28 (33.7)                   24 (25.3)

Abbreviations: PSA=prostate-specific antigen; pts=patients.

T and N staging refers to pathological staging for patients treated with surgery and to biopsy and radiological (CT and MRI) staging for patients treated with radical radiotherapy.

###### Expression patterns of LDH5 and MIB1 in biopsy and surgical specimens

  **Parameter**               **All cases (178 pts)**   **Biopsy (83 pts)**   **Surgical (95 pts)**  ***P*****-value**
  -------------------------- ------------------------- --------------------- ----------------------- -------------------
  **% LDH5 (cytoplasmic)**                                                                           
  Median (range)                    60 (0--100)             50 (0--100)            60 (0--100)       0.71
  **% LDH5 (nuclear)**                                                                               
  median (range)                    10 (0--100)             0 (0--100)             15 (0--70)        0.10
  **LDH5 groups**                                                                                    
  Low/neg                               61                      31                     30            0.43
  High                                  117                     52                     65             
  **% MIB1 (nuclear)**                                                                               
  Median (range)                     3 (0--30)               5 (0--30)              3 (0--20)        0.12
  **MIB1 groups**                                                                                    
  Low                                   134                     60                     74            0.48
  High                                  44                      23                     21             

Abbreviations: LDH5=lactate dehydrogenase 5; PSA=prostate-specific antigen; pts=patients.

###### Association of LDH5 and MIB1 with histopathological variables and PSA levels

                               **T-stage**   **Gleason score**   **PSA**   **MIB1**                   
  ---------------------------- ------------- ------------------- --------- ---------- ----- ---- ---- ----
  **(A) Biopsy specimens**                                                                            
  **LDH5**                                                                                            
   Neg/low                     31            0                   29        2          24    7    28   3
   High                        44            8                   39        13         21    21   32   20
   *P*-value                   0.02          0.04                0.14      0.005                      
  **MIB1**                                                                                            
   Low                         58            2                   55        5          44    16         
   High                        17            6                   13        10         11    12         
   *P*-value                   0.004         0.0006              0.03                                 
  **PSA**                                                                                             
   ⩽15                         53            2                   49        6                           
   \>15                        22            6                   19        9                           
   *P*-value                   0.01          0.03                                                     
  **(B) Surgical specimens**                                                                          
  **LDH5**                                                                                            
   Neg/low                     28            2                   27        3          25    5    28   2
   High                        49            16                  52        13         46    19   46   19
   *P*-value                   0.04          0.37                0.21      0.01                       
  **MIB1**                                                                                            
   Low                         64            10                  66        8          61    13         
   High                        13            8                   13        8          10    11         
   *P*-value                   0.02          0.006               0.003                                
  **(C) All cases**                                                                                   
  **LDH5**                                                                                            
   Neg/low                     59            2                   56        5          49    12   56   5
   High                        93            24                  91        26         67    40   78   39
   *P*-value                   0.001         0.02                0.02      \<0.0001                   
  **MIB1**                                                                                            
   Low                         122           12                  121       13         105   29         
   High                        30            14                  26        18         21    23         
  * P*-value                   0.0008        \<0.0001            0.0002                               

Abbreviations: LDH5=lactate dehydrogenase 5; PSA=prostate-specific antigen.

###### Univariate and multivariate analysis of biochemical relapse-free survival (BRFS) and of local relapse

                            **Univariate (Kaplan**--**Meier)**   **Multivariate (Cox regression)**          
  ------------------------- ------------------------------------ ----------------------------------- ------ ----------
  **Biochemical relapse**                                                                                   
  **Parameter**                                                                                             
   T-stage                  2.51                                 0.36                                2.79   0.12
   Gleason                  8.82                                 **0.007**                           1.74   0.47
   MIB1                     5.63                                 **0.01**                            2.60   0.14
   LDH5                     5.12                                 **0.01**                            1.88   **0.05**
   PSA                      5.10                                 **0.01**                            3.30   **0.03**
  **Local relapse**                                                                                         
  T-stage                   2.99                                 0.53                                1.00   0.98
  Gleason                   9.10                                 **0.04**                            1.30   0.21
  MIB1                      3.44                                 0.28                                1.33   0.41
  LDH5                      5.88                                 **0.03**                            1.00   0.97
  PSA                       12.5                                 **0.003**                           1.00   0.95

Abbreviations: LDH5=lactate dehydrogenase 5; PSA=prostate-specific antigen.

Results refer to comparison of worse with better outcome groups. Bold entries mark significant values.
